UCB is a global biopharmaceutical company headquartered in Belgium, with operations in nearly 40 countries. Guided by the principle “Inspired by Patients. Driven by Science,” the company develops medicines and support solutions for people living with severe neurological and autoimmune diseases. Its areas of focus include conditions such as epilepsy, psoriasis, osteoporosis, and other chronic illnesses.

UCB brings together scientific research, patient insights, and global expertise to address unmet medical needs and improve quality of life. Its innovation activities span drug discovery, clinical development, digital health, patient engagement, and partnerships with academic institutions and biotechnology companies. The company also shares scientific publications and information about its clinical studies and development pipeline.

Beyond medicines, UCB offers UCBCares, a patient support program providing practical, personal guidance to people with chronic diseases and healthcare professionals throughout the treatment journey. Its broader work includes promoting equitable access to medicines, supporting women of childbearing age living with chronic conditions, and advancing sustainability, inclusion, wellbeing, and ethical business practices.